StoryRegulatory
REPROGRAM trial of metformin, fisetin and spermidine in over-70s receives UK ethics approval
Wellcome LeapDynamic Resilience
A UK research ethics committee gave a favourable opinion to REPROGRAM, a University of Birmingham trial funded through Dynamic Resilience. Sixty healthy adults over 70 take one of three candidate anti-aging drugs for three weeks, followed by blood tests and fat biopsies to see whether underlying aging processes change.
- Sponsor: University of Birmingham; site: Queen Elizabeth Hospital Birmingham
- 60 participants, 20 per drug
- Drugs: metformin, fisetin, spermidine
- Approved by East of England - Cambridge Central ethics committee